Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02569957CT.gov Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Endometrial Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Acetylcysteine (this asset) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | CCC · 53 |
| Nogitecan | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | CCC |
| Olaparib | National Cancer Institute (NCI) | P2 | CCC |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | National Cancer Institute (NCI) | P2 | CCC |
Other indications for Acetylcysteine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Idiopathic Pulmonary Fibrosis | — | P4 | BBB · 74 |
| Schizophreniform Disorder | — | P4 | BBB · 74 |
| Pulmonary Fibrosis | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- NogitecanSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityCCC
- OlaparibNational Cancer Institute (NCI)CCC
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerNational Cancer Institute (NCI)CCC
Citation
Floatz Terminal. Acetylcysteine in Ovarian Endometrial Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/acetylcysteine-ovarian-endometrial-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →